We share a passion for helping our clients grow

For over 40 years, Kx Advisors (operating as the healthcare consulting practice of Kaiser Associates) have provided advisory services to help leading pharmaceutical, biotechnology and medical technology companies fully capitalize on product opportunities, navigate the environment with greater certainty, and maximize the lifetime commercial value of their portfolios.

We do this by conducting comprehensive primary research and data-driven analysis at all stages of the product lifecycle to inform the decision making of sales, marketing and strategy executives.

The Kx approach establishes the required fact base to vet critical decisions and brings together data from disparate sources to develop holistic strategies.

With offices in Washington D.C, London, and Boston, Kx Advisors possesses the unique ability to generate global insights from physicians, thought leaders, patients, competitors, partners, regulators, suppliers, and payers.

The Kx approach establishes the required fact base to vet critical decisions and brings together data from disparate sources to develop holistic strategies.

How we’re different

We focus on growth strategy

Unlike large consulting firms who toggle between operational work and heterogenous strategy work, we live and breathe healthcare growth strategy. As a result, we have developed deep expertise in exploring new business models, evaluating new technologies, entering new markets, and capitalizing on new policies. Our focus drives results.

We prioritize pragmatism and clarity

We pride ourselves on developing elegant solutions to complex problems. We share a passion for helping our clients devise winning strategies and gain organization buy-in through clear business cases, impactful storytelling, and actionable recommendations.

We believe in data-driven decision making

Insight generation and quantitative rigor define our consulting approach. We are experts at designing research to inform quantitative models, developing forecasts in emerging and innovative markets, and quantifying what is difficult to quantify.

We deliver a first-class client experience

We value collaboration and partnership above all else and design our engagements to follow a highly iterative process. We start fast, deliver against compressed timelines and respond to changing client needs with agility. Our senior leaders remain actively involved throughout our engagements and set a high standard of excellence.

Leadership Team

Dan O’Neill

Managing Partner

Dan O’Neill is a Managing Partner at Kx Advisors. He is based in Washington, DC.

Dan has significant experience developing commercial growth strategies for leading Pharmaceutical, Medical Device and Health Technology clients. Since joining Kaiser Associates in 2006, Dan has developed expertise across all major therapeutic areas and project types. Specific emphases include commercial due diligence, strategic marketing, product launch planning, market opportunity assessments, and competitive strategy. He has expertise in integrated research and quantitative modeling techniques related to product pricing and forecasting.

Dan started his career in finance and banking where he developed his quantitative background. Dan holds an MBA from the McDonough School of Business at Georgetown University and a BBA from the University of Kentucky.

Bob Serrano

Managing Partner

Bob Serrano is a Managing Partner at Kx Advisors. He is based in Washington, DC.

Bob has nearly 20 years of experience in the healthcare industry, specializing in specialty pharma, interventional medicine, and clinical diagnostics. Bob has extensive expertise in building growth strategies across therapeutic areas including oncology, dermatology, neurology, immunology, and cardiology. Prior to Kaiser Associates and Kx Advisors, Bob held several strategy and sales roles at Abbott (now AbbVie), and led North American laboratory marketing for QIAGEN’s molecular diagnostics business.

Bob earned an MBA from the Kellogg School of Management at Northwestern University, and a Master’s in Health Administration and a BS in Nutritional Science from Cornell University.

Jenna Riffell

Managing Partner

Jenna Riffell is a Managing Partner at Kx Advisors, based in London, UK, where she leads Kx’s European practice.

Jenna has advised Fortune 500 pharmaceutical and biotech companies on growth strategy across the value chain. She specializes in pharma/biotech, health IT, and medical devices, with particular expertise in dermatology, ophthalmology, rare diseases, and oncology. Her work includes portfolio strategy, geographic expansion strategy, commercial due diligence, strategic marketing, and launch planning.

Jenna holds a PhD in Biochemistry and Molecular Biology and a BSCh, Combined Honors in Chemistry and Biochemistry, from the University of British Columbia. She also completed a postdoctoral fellowship at the Institute of Cancer Research in London, before moving into consulting via boutique life science consultancies prior to joining Kaiser in 2015.

Sean Vander Linde


Sean Vander Linde is a Partner at Kx Advisors and is based in Washington, DC.

Sean brings deep experience leading engagements across the healthcare value chain with provider, health IT, biopharma, and medical device companies. His expertise includes advising clients on corporate strategy, market opportunity assessments, new product launch, and commercial due diligence. Prior to joining Kaiser Associates and Kx Advisors, he worked at L.E.K. Consulting and PwC focusing on healthcare.

Sean holds an MBA from the Tuck School of Business at Dartmouth and a BA in Political Science from the University of North Carolina at Chapel Hill.

Evelyn Tee

Vice President

Evelyn Tee is a Vice President at Kx Advisors based in Washington, DC.

Evelyn leverages deep experience in the cardiology, congenital disorder, nephrology, and vascular disease sectors to optimize and grow global MedTech and biopharmaceutical clients. Evelyn’s expertise includes: portfolio and strategic planning, competitive assessments, global market expansion, product optimization, and commercial transformation.
She has been recognized by Consulting Magazine as one of the most influential consultants globally, winning the 2023 Top Consultant Award in Client Service.

Prior to Kx Advisors, Evelyn held strategy consulting roles with the Boston Consulting Group and the Life Sciences Advisory Practice of EY. She holds an MBA in Operations and Marketing from the Wharton School at the University of Pennsylvania and is a Joseph Wharton Fellow. She graduated with a BA in Mathematical Methods in Social Sciences (MMSS), Economics, and International Studies from Northwestern University.

Chris Waybill

Vice President

Chris Waybill is a Vice President at Kx Advisors and is based in Boston, MA.

Chris works closely with clients to develop tailored growth strategies across all of Kx’s key sectors and therapeutic areas. He has developed specific expertise in dermatology, interventional medicine, and health IT. Chris’s functional expertise spans a broad range of services, including financial modeling and forecasting, inorganic growth strategy, pricing and market access, commercial operations, and data analytics.

Prior to joining Kaiser Associates and Kx Advisors, Chris worked as a power systems engineer at Clark Energy & Structured Finance. Chris holds a B.S.E in Mechanical Engineering & Materials Science from the Pratt School of Engineering at Duke University.

Brett Larson

Vice President

Brett Larson is a Vice President at Kx Advisors and is based in Boston, MA.

Brett has an extensive track record of identifying organic growth and M&A opportunities for leading biopharma clients. His approach incorporates deep analytical rigor, competitive intelligence, and market research to support actionable recommendations. Brett’s particular expertise lies in forecasting, portfolio prioritization, and due diligence for rare disease, cardiometabolic, and medical aesthetics companies.

Prior to joining Kx Advisors, Brett worked at SVB Leerink providing investment banking research coverage for emerging biotech companies and at Trinity as a strategy consultant to biopharma and medical device clients. He started his career in clinical research focused on trauma physiology at the University of Vermont. Brett holds an Executive MBA from Quantic School of Business & Technology and a BA in Chemistry from Amherst College.

David Geschwind


David is a Principal at Kx Advisors and is based in San Francisco, CA.

David has extensive experience leading growth strategy engagements for Pharma, Biotech, MedTech, and Digital Health clients.  Specifically, he advises clients on product launch strategy, commercial operations, financial modelling, forecasting, commercial due diligence, pricing, and market access.

David’s therapeutic areas of expertise include interventional medicine, medical aesthetics, eye care, dermatology, and oncology.

David holds a B.A. in Computer Science and Economics from Swarthmore College.

Chloe Lok


Chloe has nearly 10 years of experience in the healthcare industry, leading engagements in pharma, biotech, and digital health with particular expertise in the areas of respiratory, oncology, psychiatry, dermatology and rare diseases. She brings deep experience in qualitative and quantitative primary research techniques, as well as portfolio and strategic planning, strategic marketing, patient journey mapping, and financial modelling and forecasting.

Chloe holds an MSc in Management from Imperial College Business School of Imperial College London, and a BSc in Biochemistry from the University of Reading. Merging her passion for both business and science, Chloe launched her consulting career at a pharma and healthcare market research-based consultancy before joining Kx Advisors.

Allie Fascione-Hutchins


Allie partners with clients to develop both upstream and downstream growth strategies across all of Kx’s key sectors and therapeutic areas. Specifically, she collaborates with biopharmaceutical, medical device, and diagnostic companies, in therapeutic areas including dermatology, critical care, and cardiology. Functionally, Allie’s expertise encompasses market entry strategy, commercial due diligence, opportunity forecasting, long-term franchise planning, and commercial benchmarking. Her work integrates data analytics, competitive intelligence, and voice-of-customer research to create simple and meaningful solutions to complex problems.

Prior to Kx, Allie worked with companies in the financial services and consumer goods industries as a strategy consultant. Allie holds a B.S. with Honors in Economics, with a Mathematical Economics concentration from Haverford College.


Women at Kx graphic showing team

Empowering Our Employees At Every Step  

Gender diversity is a keystone in Kx’s inclusive company culture. Our firm supports women at each stage of their career, from new employees to established senior leaders. 

Established in 2020, Women@Kx is monthly meet-up group to provide our consultants with the tools they need to succeed while advancing gender equality in a fast-paced consulting environment. Led by Managing Partner Jenna Riffell and Vice President Evelyn Tee, the group focuses on empowering women and allies by offering opportunities for professional development, mentoring, and building meaningful networks.

Awards & Recognition

Celebrating Our Team 

Kx works each day to empower our clients and our people to change the world. We’re proud to be publicly recognized for our efforts, especially as a leader for top talent.

Kx Advisors AGS 2021 Award Blue


Our global reach

Kx Washington, D.C.

1615 L Street, NW, Suite 1300
Washington, DC 20036
+1 (202) 893 9200

Kx London

30 Crown Place, 10th Floor
London EC2A 4EB, UK
+44 20 7965 4747

Kx Boston

100 Summer Street, Suite 1600
Boston, MA, 02110